Hospital
Meridian Hospitals Corporation
Meridian Hospitals Corporation was paid $11.83M by Medicaid between Jan 2018 and Aug 2018, across 264 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoMERIDIAN HOSPITALS CORPORATION
NEPTUNE, NJ 07753
NEPTUNE, NJ 07753
33aNPI1346247368assigned 07/05/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.83M
24GClaims134,296
24DCodes billed264
24AFirst – last monthJan 2018 – Aug 2018
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#60 of 93
Median peer was paid$30.60M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 134,296 | $11.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 5,646 | 5,307 | $1.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 4,046 | 3,715 | $1.62M |
| G0378 | Hospital observation service, per hour | 12% | 1,273 | 1,123 | $1.42M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 2,774 | 2,527 | $582K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.9% | 4,282 | 1,128 | $575K |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.8% | 522 | 521 | $571K |
| S9480 | Intensive outpatient psychiatric services, per diem | 4.3% | 622 | 537 | $506K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 3.2% | 1,781 | 242 | $379K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.9% | 330 | 228 | $339K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.3% | 234 | 134 | $272K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.2% | 1,423 | 1,364 | $265K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.1% | 2,056 | 689 | $244K |
252 more codes
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.3% | 2,101 | $150K |
| 95819 | 1.1% | 151 | $130K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,118 | $118K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 130 | $110K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 37 | $104K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 163 | $101K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 83 | $89K |
| OP278 | <1% | 140 | $85K | |
| 92557 | <1% | 236 | $77K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 55 | $75K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,890 | $72K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,712 | $72K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,308 | $70K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 137 | $67K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 863 | $65K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,606 | $58K |
| 95782 | <1% | 12 | $56K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 374 | $54K |
| S9484 | Crisis intervention mental health services, per hour | <1% | 122 | $51K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,519 | $49K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 965 | $49K |
| 92587 | <1% | 229 | $47K | |
| 80053 | Comprehensive metabolic panel | <1% | 6,639 | $47K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 327 | $44K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 800 | $41K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,392 | $41K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 589 | $40K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,044 | $36K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,321 | $36K |
| 96367 | <1% | 133 | $34K | |
| 93975 | <1% | 281 | $34K | |
| 92526 | <1% | 272 | $32K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 88 | $30K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 417 | $29K |
| 92567 | <1% | 248 | $27K | |
| 97161 | <1% | 363 | $27K | |
| 97010 | <1% | 2,073 | $26K | |
| 93458 | <1% | 14 | $26K | |
| OP259 | <1% | 7,262 | $24K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,110 | $22K |
| OP379 | <1% | 1,526 | $21K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,359 | $21K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 174 | $21K |
| 70486 | <1% | 119 | $20K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,288 | $19K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 156 | $19K |
| 92523 | <1% | 43 | $19K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 117 | $18K |
| 93017 | <1% | 108 | $17K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 236 | $16K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 626 | $16K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 304 | $16K |
| 93041 | <1% | 151 | $15K | |
| OP272 | <1% | 1,508 | $15K | |
| OP279 | <1% | 1,915 | $14K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 828 | $14K |
| 93970 | <1% | 93 | $14K | |
| 36430 | <1% | 58 | $13K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 680 | $12K |
| 93971 | <1% | 174 | $12K | |
| 84484 | <1% | 1,639 | $12K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 118 | $12K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 73 | $12K |
| OP710 | <1% | 1,437 | $12K | |
| 81003 | <1% | 3,568 | $11K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 248 | $11K |
| 59025 | Fetal non-stress test | <1% | 20 | $11K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 384 | $11K |
| 96415 | <1% | 38 | $11K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 250 | $11K |
| 97165 | <1% | 106 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 414 | $10K |
| 96376 | <1% | 463 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,087 | $8K |
| 76801 | <1% | 116 | $8K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 126 | $7K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 171 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 563 | $7K |
| 71250 | <1% | 92 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 563 | $7K |
| 97162 | <1% | 118 | $7K | |
| 99152 | <1% | 109 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 539 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 559 | $6K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 482 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 317 | $6K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 88 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 740 | $6K |
| 99153 | Mod sedat endo service >5yrs | <1% | 42 | $6K |
| 76830 | Ultrasound, transvaginal | <1% | 133 | $6K |
| 80061 | Lipid panel | <1% | 469 | $6K |
| 94770 | <1% | 42 | $6K | |
| 86885 | <1% | 513 | $6K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 78 | $5K |
| 97116 | <1% | 243 | $5K | |
| 87070 | <1% | 1,051 | $5K | |
| 86901 | <1% | 723 | $5K | |
| G0451 | Development testing, with interpretation and report, per standardized instrument form | <1% | 75 | $5K |
| 90870 | <1% | 30 | $5K | |
| 72131 | <1% | 93 | $5K | |
| 86900 | <1% | 605 | $5K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 95 | $5K |
| 94762 | <1% | 59 | $5K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 169 | $5K |
| 86923 | <1% | 115 | $4K | |
| 87088 | <1% | 1,298 | $4K | |
| 96523 | <1% | 48 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 306 | $4K |
| C1769 | Guide wire | <1% | 99 | $4K |
| 83880 | <1% | 353 | $4K | |
| 70491 | <1% | 24 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 193 | $4K |
| 83735 | <1% | 649 | $4K | |
| 73562 | <1% | 283 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 496 | $4K |
| 83690 | <1% | 1,211 | $4K | |
| 80164 | <1% | 125 | $4K | |
| 86780 | <1% | 105 | $3K | |
| 73610 | <1% | 241 | $3K | |
| 74018 | <1% | 298 | $3K | |
| 87040 | <1% | 612 | $3K | |
| 80074 | <1% | 80 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 674 | $3K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 457 | $3K |
| 85610 | <1% | 844 | $3K | |
| 84439 | <1% | 276 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 238 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 43 | $3K |
| 73130 | <1% | 180 | $3K | |
| 86480 | <1% | 45 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,149 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 72 | $3K |
| 74022 | <1% | 160 | $3K | |
| 73630 | <1% | 247 | $3K | |
| 73030 | <1% | 190 | $3K | |
| 83605 | <1% | 335 | $3K | |
| 81025 | <1% | 642 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,181 | $2K |
| 87186 | <1% | 240 | $2K | |
| 70544 | <1% | 15 | $2K | |
| 92610 | <1% | 12 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 76 | $2K |
| 82803 | <1% | 166 | $2K | |
| 85730 | <1% | 493 | $2K | |
| 90715 | <1% | 139 | $2K | |
| 73110 | <1% | 146 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 54 | $2K |
| 76536 | <1% | 38 | $2K | |
| 84703 | <1% | 779 | $2K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 83 | $2K |
| 82550 | <1% | 211 | $2K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 13 | $2K |
| 84100 | <1% | 347 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 423 | $2K |
| 76870 | <1% | 37 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 134 | $2K |
| 73590 | <1% | 107 | $2K | |
| 88307 | <1% | 75 | $1K | |
| 99381 | <1% | 21 | $1K | |
| 87999 | <1% | 520 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 986 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 23 | $1K |
| 82607 | <1% | 139 | $1K | |
| 74019 | <1% | 67 | $1K | |
| 84702 | <1% | 316 | $1K | |
| 72110 | <1% | 45 | $1K | |
| 76775 | <1% | 46 | $1K | |
| 85027 | <1% | 398 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 53 | $1K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 148 | $1K |
| 82728 | <1% | 126 | $1K | |
| 72100 | <1% | 71 | $1K | |
| 88313 | <1% | 112 | $1K | |
| 87205 | <1% | 283 | $1K | |
| 88304 | <1% | 179 | $979.34 | |
| 82746 | <1% | 84 | $952.56 | |
| 83789 | <1% | 277 | $922.04 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 39 | $885.59 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 171 | $865.47 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 188 | $842.62 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 228 | $775.85 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 245 | $761.76 |
| 85378 | <1% | 304 | $705.95 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 127 | $682.64 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 132 | $681.64 |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 15 | $673.53 |
| 73080 | <1% | 42 | $664.42 | |
| 97799 | <1% | 44 | $654.81 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14 | $636.00 |
| 73140 | <1% | 82 | $631.53 | |
| 76001 | <1% | 80 | $625.69 | |
| 83550 | <1% | 125 | $623.04 | |
| 87147 | <1% | 195 | $614.48 | |
| 87581 | <1% | 171 | $609.47 | |
| 87486 | <1% | 171 | $609.47 | |
| 86140 | <1% | 455 | $594.22 | |
| 80177 | <1% | 20 | $593.24 | |
| 88312 | <1% | 95 | $590.06 | |
| 73090 | <1% | 45 | $500.04 | |
| 85651 | <1% | 356 | $443.93 | |
| 88342 | <1% | 12 | $427.27 | |
| 96127 | <1% | 155 | $418.92 | |
| 87076 | <1% | 78 | $394.52 | |
| 73502 | <1% | 66 | $387.36 | |
| 87015 | <1% | 50 | $343.20 | |
| J1815 | Injection, insulin, per 5 units | <1% | 27 | $338.41 |
| 82731 | <1% | 15 | $314.96 | |
| G0008 | Administration of influenza virus vaccine | <1% | 53 | $305.05 |
| 82248 | <1% | 53 | $299.16 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 521 | $277.80 |
| 83615 | <1% | 111 | $275.72 | |
| 86308 | <1% | 125 | $272.30 | |
| 80076 | <1% | 94 | $249.89 | |
| 85045 | <1% | 38 | $189.78 | |
| 82150 | <1% | 118 | $183.02 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 62 | $182.02 |
| 82570 | <1% | 94 | $175.70 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 284 | $174.84 |
| 87899 | <1% | 77 | $161.43 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 304 | $135.47 |
| 86665 | <1% | 40 | $135.40 | |
| 84560 | <1% | 99 | $126.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 21 | $116.68 |
| 85044 | <1% | 38 | $107.60 | |
| 86663 | <1% | 40 | $99.81 | |
| 86664 | <1% | 40 | $98.73 | |
| 87045 | <1% | 47 | $77.04 | |
| 87493 | <1% | 27 | $77.02 | |
| 86617 | <1% | 15 | $75.74 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 26 | $72.85 |
| 82010 | <1% | 84 | $69.30 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 36 | $68.41 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 28 | $67.74 |
| 86038 | <1% | 13 | $66.92 | |
| 82947 | <1% | 15 | $56.63 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 187 | $42.97 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 18 | $39.44 |
| 90686 | <1% | 12 | $34.06 | |
| 82009 | <1% | 36 | $33.70 | |
| 84145 | <1% | 13 | $29.40 | |
| Q9953 | Injection, iron-based magnetic resonance contrast agent, per ml | <1% | 75 | $25.52 |
| 85014 | <1% | 18 | $18.83 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 12 | $18.73 |
| 85018 | <1% | 18 | $17.85 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 31 | $14.77 |
| 84156 | <1% | 31 | $12.60 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 106 | $10.98 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 32 | $8.66 |
| 82270 | <1% | 12 | $7.26 | |
| 88300 | <1% | 44 | $5.18 | |
| 84132 | <1% | 14 | $3.90 | |
| 84311 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGANTNER, JOHN (SENIOR VP, FINANCE & CFO)
| Provider | Location | Paid |
|---|---|---|
| Meridian Hospitals Corporation | Brick, NJ | $4.72M |
| Meridian Hospitals Corporation | Red Bank, NJ | $2.31M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.